Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Equivalents: 2012-2025

Historic Cash & Equivalents for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $630.2 million.

  • Ascendis Pharma A's Cash & Equivalents fell 8.26% to $630.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.2 million, marking a year-over-year decrease of 8.26%. This contributed to the annual value of $605.6 million for FY2024, which is 43.53% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Cash & Equivalents of $630.2 million as of Q3 2025, which was up 12.69% from $559.2 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Cash & Equivalents peaked at $848.1 million during Q1 2022, and registered a low of $278.6 million during Q2 2024.
  • For the 3-year period, Ascendis Pharma A's Cash & Equivalents averaged around $501.4 million, with its median value being $538.0 million (2023).
  • As far as peak fluctuations go, Ascendis Pharma A's Cash & Equivalents tumbled by 40.17% in 2023, and later soared by 100.74% in 2025.
  • Ascendis Pharma A's Cash & Equivalents (Quarterly) stood at $510.5 million in 2021, then decreased by 11.12% to $453.8 million in 2022, then decreased by 7.01% to $421.9 million in 2023, then skyrocketed by 41.71% to $597.9 million in 2024, then dropped by 8.26% to $630.2 million in 2025.
  • Its Cash & Equivalents was $630.2 million in Q3 2025, compared to $559.2 million in Q2 2025 and $544.8 million in Q1 2025.